From Boardroom to Benchtop: Paul LaViolette Joins SVLS
This article was originally published in Start Up
Paul LaViolette spent more than a decade at Boston Scientific where, among other things, he helped build the company into a cardiovascular powerhouse. LaViolette announced his retirement from BSC last year and after considering a number of opportunities, decided to join Boston-based SVLS as a venture partner. LaViolette enters venture investing at a challenging time, during which the industry will face what he calls "a Darwinian process with more operational pressure" at start-ups and a likely weeding out of many companies. In this interview, LaViolette describes how the venture world of 2008 feels a lot like Boston Scientific in 1993 -- a world of small, driven companies with huge operational challenges and huge opportunities.
You may also be interested in...
At FDC-Windhover's October IN3 East conference, we asked a distinguished panel of experienced venture capitalists to share their insights on the downturn in medtech venture investing. We invited our panelists to weigh in on the role of the current crisis in the second and third quarter slowdown in device investing and what it would mean going forward for a sector that had been so frothy just a short time earlier.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.